What is the half-life of DSIP?

DSIP's plasma half-life is reported as short, on the order of minutes, consistent with a small linear peptide cleared rapidly. Its circulating exposure is brief, so research models treat it as a single timed window rather than a compound that maintains a steady level across a day.

Why does timing matter more than half-life for DSIP?

Because DSIP is studied in relation to the rest phase and sleep architecture, the informative variable is when in the circadian cycle its short window is placed — not how long it persists. The half-life sets the size of the window; the circadian research question sets where it goes. That is what distinguishes DSIP's design from a pre-task nootropic peptide.

Does DSIP accumulate with repeated use in research models?

Its short plasma clock means research protocols generally model it as a single timed reagent rather than something that builds up over days. Cadence follows the rest-phase question being asked, not a maintained plateau — the same acute-window logic seen with other short-half-life peptides, applied to a circadian design.

What should a DSIP COA confirm?

Identity first: a correct COA confirms the nine-residue DSIP sequence by mass spec alongside HPLC purity, not just a purity number. A truncated or substituted analogue would behave differently. Titan's DSIP ships with an HPLC main-peak result against a ≥99% internal purity target and mass-spec identity confirmation on a lot-matched release sheet.

Is DSIP approved for human use?

Titan Peptide Lab supplies DSIP strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption, and not for diagnostic, therapeutic, or preventative use. The kinetic figures on this page are a laboratory reference, not medical or dosing advice.

DSIP · delta sleep-inducing peptide · pharmacokinetics · research use only

DSIP half-life: a short clock where timing matters more than total.

DSIP — delta sleep-inducing peptide — is a linear nine-residue peptide, and its reported plasma half-life is short, on the order of minutes. With most peptides the headline question is how long the molecule lasts; with DSIP the more informative variable in the literature is when in the circadian cycle it is studied, because it is investigated in relation to the rest phase and sleep architecture. A short half-life is not a limitation for that kind of work — it suits a compound modelled around a specific window rather than a maintained level. This page explains DSIP's clearance, why rest-phase timing dominates the research design, and what its COA should confirm. It is a laboratory reference, not a human protocol or medical advice.

DSIP nasal spray — $62.99 DSIP dosage reference

Short in plasma — minutes

DSIP's reported plasma half-life is short, on the order of minutes, consistent with a small linear peptide cleared rapidly without a stabilising modification. That means circulating exposure is brief, and a research model does not assume the compound holds a steady level across a day. The interesting clock for DSIP is not how long it persists but where its window is placed.

How that shapes timing →

Rest-phase, not pre-task, timing

Unlike a nootropic peptide modelled to a pre-task window, DSIP is studied in relation to the rest phase and sleep architecture — so research protocols tend to position its short window against the circadian cycle rather than an acute cognitive task. The half-life sets the size of the window; the circadian framing sets where it goes. That distinction is what separates DSIP timing from the other nasal peptides Titan stocks.

Handling a sleep-research peptide →

Window, not accumulation

Because the plasma clock is short, DSIP behaves as a single timed reagent rather than something that builds up over days. Research cadence follows the rest-phase question being asked, not a maintained plateau. This is the same acute-window logic seen in other short-half-life peptides, applied to a circadian rather than a task-based design.

DSIP vs Selank compared →

A linear nonapeptide

DSIP is a linear nine-residue sequence with no disulfide bridge and no stabilising terminus, which is consistent with its short reported half-life. That structure is what a COA must confirm — the full sequence, not a truncated or substituted analogue that would clear or behave differently. Identity is the first verification step for any short-half-life research peptide.

Why the sequence matters on a COA →

Identity, not just purity

A bare purity percentage does not prove you received DSIP — a correct COA confirms the nine-residue identity by mass spec alongside HPLC purity. Titan's DSIP nasal spray ships against an HPLC main-peak result with a ≥99% internal purity target and mass-spec identity confirmation on a lot-matched release sheet, so the molecule's reported kinetics actually apply to what is in the vial.

See the testing workflow →

Research-use framing

DSIP is supplied strictly as a research-use-only reagent. The half-life and timing figures here are reproduced as a laboratory reference for in-vitro and modelling work — not instructions for human use, and not a claim about sleep, sedation, or any physiological effect. Nothing on this page is medical or dosing advice.

Research-use policy →

The detail, in plain terms

A short window, placed deliberately.

DSIP's kinetics make sense once half-life and circadian framing are read as separate variables: a short clock sets the window size, the rest-phase question sets its position. These are the figures a research protocol weighs, reproduced as a reference, not a human protocol.

Compound: DSIP — delta sleep-inducing peptide, a linear nine-residue sequence.
Plasma half-life: Short — reported on the order of minutes.
Structure: Linear, no disulfide bridge or stabilising terminus.
Research framing: Studied against the rest phase / circadian cycle, not a pre-task window.
Resulting cadence: Single timed window — not multi-day accumulation.
Titan format: Metered nasal spray, $62.99 — no reconstitution required.

Questions researchers ask

Before you order.

What is the half-life of DSIP?: DSIP's plasma half-life is reported as short, on the order of minutes, consistent with a small linear peptide cleared rapidly. Its circulating exposure is brief, so research models treat it as a single timed window rather than a compound that maintains a steady level across a day.
Why does timing matter more than half-life for DSIP?: Because DSIP is studied in relation to the rest phase and sleep architecture, the informative variable is when in the circadian cycle its short window is placed — not how long it persists. The half-life sets the size of the window; the circadian research question sets where it goes. That is what distinguishes DSIP's design from a pre-task nootropic peptide.
Does DSIP accumulate with repeated use in research models?: Its short plasma clock means research protocols generally model it as a single timed reagent rather than something that builds up over days. Cadence follows the rest-phase question being asked, not a maintained plateau — the same acute-window logic seen with other short-half-life peptides, applied to a circadian design.
What should a DSIP COA confirm?: Identity first: a correct COA confirms the nine-residue DSIP sequence by mass spec alongside HPLC purity, not just a purity number. A truncated or substituted analogue would behave differently. Titan's DSIP ships with an HPLC main-peak result against a ≥99% internal purity target and mass-spec identity confirmation on a lot-matched release sheet.
Is DSIP approved for human use?: Titan Peptide Lab supplies DSIP strictly as a research-use-only reagent for in-vitro laboratory work — not for human or animal consumption, and not for diagnostic, therapeutic, or preventative use. The kinetic figures on this page are a laboratory reference, not medical or dosing advice.